CryoCell International Inc (CCEL)vsDaVita HealthCare Partners Inc (DVA)
CCEL
CryoCell International Inc
$3.99
-4.09%
HEALTHCARE · Cap: $35.48M
DVA
DaVita HealthCare Partners Inc
$183.14
-0.32%
HEALTHCARE · Cap: $11.73B
Smart Verdict
WallStSmart Research — data-driven comparison
DaVita HealthCare Partners Inc generates 44907% more annual revenue ($14.01B vs $31.13M). DVA leads profitability with a 6.0% profit margin vs -7.9%. DVA appears more attractively valued with a PEG of 0.45. DVA earns a higher WallStSmart Score of 70/100 (B).
CCEL
Buy50
out of 100
Grade: C-
DVA
Strong Buy70
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+33.9%
Fair Value
$5.05
Current Price
$3.99
$1.06 discount
Margin of Safety
-12.9%
Fair Value
$127.80
Current Price
$183.14
$55.34 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 129 in profit
Earnings expanding 72.1% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Every $100 of equity generates 81 in profit
Earnings expanding 55.8% YoY
Conservative balance sheet, low leverage
Attractively priced relative to earnings
Areas to Watch
Smaller company, higher risk/reward
Revenue declined 1.9%
Distress zone — elevated risk
Currently unprofitable
6.0% margin — thin
Weak financial health signals
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : CCEL
The strongest argument for CCEL centers on Return on Equity, EPS Growth, Debt/Equity. PEG of 1.34 suggests the stock is reasonably priced for its growth.
Bull Case : DVA
The strongest argument for DVA centers on PEG Ratio, Return on Equity, EPS Growth. PEG of 0.45 suggests the stock is reasonably priced for its growth.
Bear Case : CCEL
The primary concerns for CCEL are Market Cap, Revenue Growth, Altman Z-Score.
Bear Case : DVA
The primary concerns for DVA are Profit Margin, Piotroski F-Score, Altman Z-Score.
Key Dynamics to Monitor
CCEL profiles as a turnaround stock while DVA is a value play — different risk/reward profiles.
DVA carries more volatility with a beta of 0.83 — expect wider price swings.
DVA is growing revenue faster at 5.2% — sustainability is the question.
DVA generates stronger free cash flow (320M), providing more financial flexibility.
Bottom Line
DVA scores higher overall (70/100 vs 50/100). CCEL offers better value entry with a 33.9% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CryoCell International Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Cryo-Cell International, Inc. is dedicated to cell processing and cryogenic cell storage with a focus on collecting and preserving umbilical cord blood stem cells for family use. The company is headquartered in Oldsmar, Florida.
DaVita HealthCare Partners Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
DaVita Inc. provides kidney dialysis services through a network of outpatient dialysis centers in the United States.
Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?